Dysferlin loss in iMPs results in cell-autonomously altered transcriptome, secretome, and endocytic function, which may contribute to LGMDR2 muscle pathology and disease progression.
Abstract
Limb-girdle muscular dystrophy R2/2B (LGMDR2/2B) is an untreatable and progressive late-onset skeletal muscle disease caused by the loss of a membrane-repair protein dysferlin. Even before disease symptom onset, LGMDR2 muscles are infiltrated by pro-inflammatory macrophages (MP), implicating immune cells in disease pathogenesis. While MPs express dysferlin, defining the cell-autonomous roles of dysferlin in MP function has been challenging in vivo due to complex multicellular interactions and altered microenvironment in LGMDR2 muscle.
To address this, we generated human induced pluripotent stem cell (hiPSC)-derived macrophages (iMPs) from three healthy and three LGMDR2 donors to delineate cell-autonomous roles of dysferlin in macrophage: 1) polarization, 2) transcriptional profile, 3) secretome, and 4) phagocytotic and endocytic function.
Despite exhibiting comparable polarization under well-characterized pro- and anti-inflammatory cues, RNAseq analyses revealed downregulation of Gene Ontology terms related to cytokine secretion, phagocytosis, and receptor-mediated endocytosis in LGMDR2 iMPs. Proteomic analysis of iMP conditioned media revealed significant differences in 72 secreted proteins, including numerous chemokines, cytokines, and growth factors, suggesting an altered secretory phenotype. Functional assays found no significant differences in the phagocytosis of E. coli bioparticles or fluorescent myotube debris. However, receptor-mediated endocytosis of AcLDL was significantly lower in both M0 and M2 LGMDR2 vs. healthy iMPs. Pharmacological screens identified clathrin-dependent endocytosis as the primary pathway for AcLDL uptake in both genotypes, with altered clathrin trafficking and reduced scavenger receptor expression likely underlying LGMDR2 endocytic deficits.
Overall, dysferlin loss in iMPs results in cell-autonomously altered transcriptome, secretome, and endocytic function, which may contribute to LGMDR2 muscle pathology and disease progression.
Jain Foundation grant, NIH grant 1R01AR082979-01, National Science Foundation Graduate Research Fellowship
Immune Mechanisms of Human Disease (HUM)
It is demonstrated that TMZ mitigates dystrophic pathology by targeting the ATP6AP2 signaling axis and dampening macrophage-mediated inflammatory responses, highlighting its potential as a novel immunopharmacological therapeutic strategy for DMD.
Lin Zhou, Yu Zhang, Xinxin Tan et al.· International Immunopharmaco...· 0 citations
Dysferlin is identified as a regulator of membrane homeostasis in myeloid cells, defective membrane-stress adaptation as trigger of NLRP3 inflammasome activation is established, and a novel IL-1 mediated autoinflammatory disease caused by gain-of-function DYSF mutations is defined.
Farzana Bhuyan, Clinton J. Bradfield, Amitava Roy et al.· medRxiv· 0 citations
This work generates human induced pluripotent stem cell-derived midbrain dopaminergic neurons using both a 2D differentiation protocol and a recently developed 3D method based on the microencapsulation of hiPSCs in small alginate/fibronectin beads.
A. Zanon, E. Kerschbamer, D. Riekschnitz et al.· Communications Biology· 0 citations
It is suggested that bidirectional disruptions to normal LRRK2 function break immune homeostasis and immune cell function should be carefully considered when targeting LRRK2 kinase activity in patients with PD.
Robert C. Sharp, Shannon C. Wall, Jordan C. Follet et al.· bioRxiv· 0 citations
It is suggested that MAGI2 acts as a negative regulator of myofibroblast differentiation by stabilizing PTEN, whereas PREX2 is aberrantly expressed in the fibrotic milieu, negatively modulating MAGI2, thereby accelerating pulmonary fibrosis.
Yozo Sato, K. Kamio, Yasuhiro Terasaki et al.· American Journal of Physiolo...· 0 citations
A variant-specific insight is revealed into CMT2A disease mechanisms and HDAC6 is confirmed as a promising target for further therapeutic development by showing that mitochondrial trafficking defects could be alleviated by treatment with an HDAC6 inhibitor.
Lydia H. Jestice, Larissa Butler, Rebecca A. Lea et al.· JCI Insight· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.